Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 11 of the 90 sources its claims cite were checked for support.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.
Overview
CoChat Summary
TL;DR
This review discusses controversies in the pathogenesis, diagnosis, and treatment of polycystic ovary syndrome (PCOS), focusing on insulin resistance, inflammation, and hyperandrogenism. It argues that therapy must be individualized and that, apart from combined oral contraceptives (COCs), most drugs used for PCOS remain off-label, with larger and longer-term studies needed.
Key findings
- PCOS prevalence varies by diagnostic criteria: 4–8% by NIH/NICHD criteria and approximately 18% by Rotterdam criteria; the Rotterdam criteria are endorsed by a recent international evidence-based guideline.
- Insulin resistance is common in PCOS, worsened by hyperandrogenism-related adipose tissue accumulation, and compensatory hyperinsulinemia stimulates ovarian theca androgen production and decreases hepatic SHBG synthesis, increasing total and free androgens.
- Chronic low-grade inflammation is associated with increased white blood cell count, CRP, IL-6, IL-18, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1; aldosterone and the aldosterone/renin ratio are often increased in PCOS and may accentuate inflammation and metabolic/cardiovascular disorders.
- Treatment should start with lifestyle improvement; metformin, inositols (with a MYO:DCI ratio of 40:1 described as most effective), GLP-1 receptor agonists, and SGLT2 inhibitors are discussed, while COCs and antiandrogens have benefits and risks; spironolactone is preferred among antiandrogens because it also has anti-inflammatory action.
Methods
- Narrative review of published literature on PCOS pathogenesis, diagnosis, and treatment, with emphasis on insulin resistance, inflammation, and hyperandrogenism.
- The paper synthesizes prior studies and guidelines, including diagnostic criteria, PCOS phenotypes A–D, androgen measurement issues, insulin resistance assessment, and therapeutic options.
- No primary data collection, new patient sample, or systematic meta-analysis is described.
Limitations
- Stated: many PCOS drugs are off-label; more randomized controlled trials and long-term studies are needed; larger samples are needed to evaluate new therapies and inflammation in adipose tissue; microbiome role requires further study; studies of third-generation contraceptives are short-term, discordant, and often limited in patient numbers.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or new empirical data, so conclusions rely on interpretation of cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 7 Not valid · 66 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The administration of drugs with anti-androgenic activity improves insulin resistance [26].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 4. The Pathogenetic Role of Hyperandrogenism in PCOS
What the sources say
- Disputedcites [26] Armanini, 2016, Spironolactone in the treatment of polycystic ovary syndrome, Expert Opin. Pharmacother. sourceExperimental — accuracy not yet measured
Section 3 (page unavailable) discusses hormonal contraceptives containing progestins with antiandrogenic activity, but says the available data do not demonstrate a positive or negative effect on insulin resistance. The paper discusses spironolactone’s benefits for androgen-related symptoms; it does not establish the claimed improvement in insulin resistance. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progression of the disease [4].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 1. Introduction
What the sources say
- Supportedcites [3] Dumesic, 2020, Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective, Curr. Opin. Endocr. Metab. Res. source
The Insulin resistance section states that 60–95% of women with PCOS have insulin resistance, supporting the description of it as very common. (LLM, conf=0.95)
- Not checked yetcites [4] Dunaif, 2012, Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications, Endocr. Rev. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 3. The Pathogenetic Role of Inflammation in PCOS
What the sources say
- Partly supportedcites [18] Makki, 2013, Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines, ISRN Inflamm. sourceExperimental — accuracy not yet measured
Our copy supports the general half of the claim: Section 1 states that obesity is a proinflammatory condition and that 'white adipose tissue (WAT) is the key site mediating systemic inflammation,' and Section 1.1 that obese adipose tissue mainly releases proinflammatory cytokines (TNF-α, IL-6, leptin, resistin...) contributing to insulin resistance. PCOS appears only once, in Section 1, where 'polycystic ovarian diseases' is listed among metabolic diseases for which excess adiposity is an established risk factor (citing ref [1]) — a risk-factor statement, not a pathogenic mechanism. The source nowhere attributes to adipose tissue a pro-inflammatory role in the pathogenesis of PCOS specifically; its scope is obesity-induced inflammation and insulin resistance/T2D (Section 3, Concluding Remarks). The PCOS-specific causal/pathogenic part of the citing sentence is unsupported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ideally, a progestin with the lowest possible androgenic action such as cyproterone acetate, chlormalidone, and drospirenone should be used. However, they have been associated with increased risk of venous thrombosis [65,66,67].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.2. Hormonal Contraceptives
What the sources say
- Not checked yetcites [65] Bird, 2013, Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?, J. Thromb. Haemost. source
- Partly supportedcites [66] Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA sourceExperimental — accuracy not yet measured
The COMMENT section reports increased venous-thrombosis risk with estrogen plus progestin in postmenopausal women. But the Participants section identifies the studied progestin as medroxyprogesterone acetate; the paper does not establish the claimed association for cyproterone acetate, chlormalidone, or drospirenone, or address their androgenic action. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [67] Gronich, 2011, Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study, CMAJ sourceExperimental — accuracy not yet measured
The Results report increased venous-thrombosis risk with drospirenone-containing contraceptives relative to second- and third-generation contraceptives. They do not establish the same association for cyproterone acetate or chlormadinone; the Results explicitly say the chlormadinone sample was too small to analyze. The source therefore supports the risk claim for drospirenone, but not for all three named progestins. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.1. Insulin Sensitizers
What the sources say
- Partly supportedcites [61] Montandon, S.A., and Jornayvaz, F.R. (2017). Effects of antidiabetic drugs on gut microbiota composition. Genes, 8. sourceExperimental — accuracy not yet measured
Section 3 (Discussion) describes metformin as the most studied medication and reports increases in potentially beneficial bacteria, supporting the composition part. But Section 2.2 (Biguanides) says its effects on diversity are diet-dependent and reports decreased bacterial diversity in mice on a high-fat diet. The paper therefore does not support an unqualified positive effect on diversity. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 79 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, chronic low-grade inflammation is commonly observed in this population, contributing to metabolic dysregulation and an increased risk of comorbidities such as T2DM and cardiovascular disease13.”
From Cross-sectional study of the relationship between dietary inflammatory index and inflammatory hormonal and metabolic profiles in polycystic ovary syndrome (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperinsulinaemia, however, can contribute to certain obesity complications or related diseases, including hormonal disorders related to sex hormones and cancer (ie, mitogenic effect of insulin).98,99”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In women, hormonal dysfunction of adipose tissue and hyperinsulinaemia (which can act as a gonadotrophin) from insulin resistance constitute the main links to development of functional hyperandrogenism or polycystic ovary syndrome.98”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“As direct assays to measure free testosterone are not entirely reliable, another useful tool for the assessment of biochemical hyperandrogenism is free testosterone calculated using the formula of Vermeulen and collogues [36].”
MethodThe Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 3×
“In skeletal muscle, the inhib ion of phosphoi sitide-3 kinase nd phosp orylation of i sulin recep or sub trate 1 le ds to impaired insulin signali g by altering the GLUT-4 xpression and glucose uptake [6,7].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The second problem is related to the various methods of measurement (fasting insulin or after glucose loading), which do not correlate with what has been found using more accurate and sophisticated laboratory methods [40].”
MethodBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · cited 1×
“In clinical practice, HOMA-IR is the most common test used in research studies to measure insulin resistance, as it has been shown to closely approximate the results of clamp studies over many years [41,42].”
ResultAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“However, this latter phenotype is not included among PCOS according to the Androgen Excess Society guideline, which suggests the presence of both hyperandrogenism and ovarian dysfunction [31].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“In particular, insulin and LH act synergistically on the theca cells, stimulating ovarian androgen production [4].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Cited by
Items 101–200 of 324
Bahreiny, S. S., Khaksar, M. A., Karamali, N., Dabbagh, M. R., Hoseinnejad, A., Fard, R. M., Bahreiny, Z. S., Aghaei, M., Sakhavarz, T., & Zahedian, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01755-3 · Cited by 10
“Hyperinsulinemia also alters endometrial receptivity by reducing glycodelin and IGFBP-1 expression, impairing spiral artery remodeling, and compromising implantation [22].”
Yu, S., Hou, C., Zhang, X., & Wei, Z. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149782 · Cited by 9
Yadav, S., Dadge, S. D., Garg, R., Goand, U. K., Agarwal, A. K., Chauhan, D., & Gayen, J. R. (2024) · Steroids · doi:10.1016/j.steroids.2024.109558 · Cited by 8
Gkantzos, A., Kalogiannis, S., & Deda, O. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00937 · Cited by 9
Gałczyńska, D., Daniluk, J., Buczek-Kutermak, A., Pruś, P., & Pluta, D. (2025) · Biomedicines · doi:10.3390/biomedicines13061341 · Cited by 8
“An increased insulin level inhibits hep-atic sex hormone-binding globulin (SHBG) synthesis, which leads to an increased level of bioavailable testosterone [3].”
Yu, D., Li, J., Wei, Q., Zhu, C., Zhang, X., Li, X., & Guo, D. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156998 · Cited by 9
Uluğ, E., & Açıkgöz, A. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00488-7 · Cited by 10
Unraveling PCOS: Exploring its causes and diagnostic challenges
Dar, M. A., Maqbool, M., Qadrie, Z., Ara, I., & Qadir, A. (2024) · Open Health · doi:10.1515/ohe-2023-0026 · Cited by 7
Yang, L., Guo, N., Wang, X., Zhang, X., He, J., Li, H., Zhou, H., & Ma, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70256 · Cited by 7
“Beyond reproductive manifestations, PCOS has been strongly associated with metabolic disorders such as insulin resistance, 5 obesity, 6 and dyslipidemia.”
Zhang, C., Lin, Z., Lin, Y., & Ma, H. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01837-6 · Cited by 9
“Excess androgens, primarily synthesized by ovarian theca cells as androstenedione and testosterone under stimulation by LH and insulin, inhibit follicle-stimulating hormone (FSH) action, compromising follicular maturation and ovulation [6, 7].”
Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers
Song, Q., Liu, L., Yang, Q., Pan, M., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1800322 · Cited by 11
Zhou, X., Ma, Q., Yan, Z., Wang, Y., Qin, J., Tong, T., Liang, R., Li, Y., Wang, Y., & Chen, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116517 · Cited by 9
Unveiling the shared genetic architecture between testosterone and polycystic ovary syndrome
Sun, S., Liu, Y., Li, L., Xiong, L., Jiao, M., Yang, J. Z., Li, X., & Liu, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-75816-0 · Cited by 9
“Testosterone (T), among the most prevalent androgens in women, predominantly arises from the conversion of androstenedione produced by the female ovaries and adrenal cortex 10 .”
BackgroundAssociation between estimated glucose disposal rate and female infertility: a cross-sectional study
Li, M., Zhang, L., Li, X., & Yan, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1474738 · Cited by 9
Elevated IGFBP7 expression in follicular granulosa cells promotes PCOS pathogenesis
Chen, L., Hui, L., Wang, Y., Yao, X., & Li, J. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167743 · Cited by 9
Zheng, X., Zhao, D., Liu, Y., Jin, Y., Liu, T., Li, H., & Liu, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115739 · Cited by 7
Dubey, P., Shi, T., Coltharp, M., & Reddy, S. (2022) · Dietetics · doi:10.3390/dietetics1020008 · Cited by 8
Mrabet, H. E., Salem, H. B., Ach, T., Abdelkarim, A. B., & Alaya, W. (2024) · SAGE Open Medicine · doi:10.1177/20503121241308997 · Cited by 8
Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms
Badejogbin, O. C., Agunloye, M. O., Chijioke‐Agu, O. E., Olubiyi, M. V., Olugbuyiro, S. O., Soetan, O. A., Bamgbose, O. A., & Olaleye, T. O. (2026) · BioMed Research International · doi:10.1155/bmri/1110229 · Cited by 7
Deng, Y.-P., Zhou, Y.-L., Wei, T.-T., He, G.-S., Zhu, Z., Zhang, S.-N., Liu, M., Xue, J.-J., Zhang, W., & Yang, X. (2024) · Medicine · doi:10.1097/md.0000000000038912 · Cited by 9
“[11,15] 18] Traditional Chinese medicine (TCM) therapies such as herbal formulas, herbal extracts, and acupuncture have become increasingly important interventions for the prevention and treatment of PCOS according to extensive data analysis.”
BackgroundKallistatin as a Potential Biomarker in Polycystic Ovary Syndrome: A Prospective Cohort Study
Yurtkal, A., & Canday, M. (2024) · Diagnostics · doi:10.3390/diagnostics14141553 · Cited by 9
“These must be adjusted based on the varying clinical symptoms [8].”
BackgroundButyrate ameliorates ovarian failure in experimental PCOS rat model by suppression of HDAC2
Olaniyi, K. S., Akintayo, C. O., Oladimeji, T. E., Areloegbe, S. E. J., Badejogbin, O. C., Bashir, A.-A. M., Agan, S. U., Fafure, A. A., Adekeye, A. O., Ajadi, M. B., et al. (2025) · Comparative Clinical Pathology · doi:10.1007/s00580-025-03633-6 · Cited by 7
“These factors perpetuate and reinforce each other, contributing to the development and progression of PCOS (Armanini et al. 2022).”
Zhang, L., Yin, C.-Q., Sun, S.-J., Teng, X.-Q., Li, D., Sun, J., & Cui, Y.-Y. (2023) · Medicine · doi:10.1097/md.0000000000035489 · Cited by 5
Hu, Z., Zeng, R., Tang, Y., Liao, Y., Li, T., & Qin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1413068 · Cited by 8
FTO gene polymorphism and susceptibility to polycystic ovary syndrome: A meta‐analysis
Zhang, C.-H., & Yu, J. (2024) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16047 · Cited by 5
Ren, M., Yang, T., Liu, M., Ma, X., Li, B., Al-Mughalles, A. S., Pei, X., & Zhang, S. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150634 · Cited by 6
Rao, M., Guo, Z., Dong, H., Ho, C. S., Chen, X., Li, J., Hong, X., You, Y., Hao, Y., Hu, P., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120210 · Cited by 5
Peng, H., Ren, J., Zhao, Y., Fang, X., Wang, X., Liu, C., & Wan, Z. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112235 · Cited by 7
Usatiuc, L. O., Pârvu, M., Pop, R. M., Uifălean, A., Vălean, D., Surd, A. O., Țicolea, M., Hîruța, A., Ranga, F., Cătoi, A. F., et al. (2025) · Antioxidants · doi:10.3390/antiox14050573 · Cited by 6
Bulu, A., Önalan, E., Yakar, B., Bulu, G., Yıldırım, S. O., Uğur, K., & Dönder, E. (2025) · Medicina · doi:10.3390/medicina61061012 · Cited by 8
“Apart from this, hypertension, cardiovascular problems, and dyslipidemia are diseases accompanying PCOS [3].”
Hidayat, S. T., Mulyantoro, I., Damas, S., & Tjandrawinata, R. R. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s409685 · Cited by 9
“12,13 Consequently, improving insulin resistance with lifestyle changes or by taking a diabetes medication is part of the current PCOS treatment.”
BackgroundThe PCOS puzzle: putting the pieces together for optimal care
Dar, M. A., Maqbool, M., & Ara, I. (2023) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2023-0102 · Cited by 7
Kwiatkowski, J., Akpang, N., Ziemkiewicz, Z., Zaborowska, Ł., & Ludwin, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178192 · Cited by 7
“It is widely recognized that adipose tissue macrophages release tumor necrosis factor-α (TNF-α ) and interleukin-6 (IL-6), which are involved in the development of insulin resistance [85].”
Begum, R. F., & Mohan, S. (2024) · Future Science OA · doi:10.2144/fsoa-2023-0245 · Cited by 8
Beyond BMI: We are discussing a new concept for the definition and diagnosis of clinical obesity
Demidova, T. Y., Кislyak, O. A., Starodubova, A. V., Nikitin, I. G., & Омариевна, У. Ф. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-183 · Cited by 5
Zhang, Y., Shi, B., Tian, Y., XU, S., & Chang, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1697275 · Cited by 11
“Dysregulation of the hypothalamic–pituitary-ovarian axis, driven by increased LH secretion, stimulates theca cell hyperplasia and enhances the expression of enzymes critical for androgen bio-synthesis, thereby promoting excessive androgen production (10).”
Łagowska, K., & Pieczyńska-Zając, J. M. (2022) · Women & Health · doi:10.1080/03630242.2022.2106529 · Cited by 7
“…untreated hyperandrogenism in women with excessive body mass, especially in cases of coexisting insulin resistance, may even result in the development of polycystic ovary syndrome (PCOS) (Armanini et al. 2022), which may affect up to 20 percent of women in reproductive age (Faghfoori et al. 2017).”
BackgroundHuang, W., Liu, C., Ding, L., Li, Y., Zhou, H., Wang, S., & Yang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1327041 · Cited by 6
Gap junctions in polycystic ovary syndrome: Implications for follicular arrest
Zhu, Y., Zhu, H., & Wu, P. (2024) · Developmental Dynamics · doi:10.1002/dvdy.706 · Cited by 4
“102 In PCOS, there is a paucity of studies exploring the relationship between connexins and IR, but work in mammals has explored the roles of connexins in the context of other IR-related diseases, such as diabetes, nonalcoholic fatty liver disease and cardiac disease.”
Hofmann, K., Oehler, M., Ruckes, C., Dionysopoulou, A., Stewen, K., Schiestl, L. J., Degirmenci, Y., Theis, S., Skala, C., Hasenburg, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40431 · Cited by 5
Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?
Wang, L., Jin, Y., Zhi, Y., Li, Z., Wang, M., Wang, B., & Wang, X. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01642-1 · Cited by 6
“Recent studies have suggested that inflammation may also contribute to the pathogenesis of PCOS [17, 18].”
Wang, J., Luo, Y., Liu, Y., Tang, X., Gu, J., Huang, Z., Lv, T., Luo, J. P., & Fang, G. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01685-4 · Cited by 5
“Currently, metformin is the first-line drug for the treatment of insulin resistance in polycystic ovary syndrome (PCOS-IR) [8], but in clinical practice, gastrointestinal symptoms such as nausea, abdominal pain, abdominal distension, diarrhea and other gastrointestinal symptoms, and in severe…”
Du, M., & Ge, H. (2025) · Medicine · doi:10.1097/md.0000000000042481 · Cited by 5
“[24] Such metabolic impairments could not only compromise maternal health but also contribute to pregnancy complications by influencing placental function and fetal development.”
Mechanistic insight into nanomedicine for polycystic ovary syndrome
Butt, M. A., Tabassum, S., Hardy, R., & Kiyani, M. M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10709-7 · Cited by 13
Zheng, B., Che, X., Chen, Z., Cheng, D., Huang, C., Zeng, Z., & Mo, Z. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70116 · Cited by 5
“Inflammation is intricately linked to ovarian function [27].”
Vieyra, E., Silva, C., Linares, R., Rosas, G., Espinoza, J.-A., Chaparro, A., Calderón, R., de la Peña, B., & Morales‐Ledesma, L. (2025) · Molecules · doi:10.3390/molecules30163407 · Cited by 6
Zhang, R., Wang, X., Mo, M., Liu, Z., & Su, L. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01453-5 · Cited by 6
Jin, B.-H., Xu, H., Zhang, Z., Fan, Y.-H., Jiang, C., Qi, S., Xiao, C.-Y., Fu, X., & Qian, L.-B. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5630 · Cited by 5
“The majority of conventional PcOS treat‑ ments primarily target insulin resistance or ovarian dysfunction, often overlooking the contribution of hyperandrogenism‑driven hepatic lipogenesis (41).”
Parsaei, M., Karimi, E., Barkhordarioon, A., Yousefi, M., & Tarafdari, A. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02719-y · Cited by 9
Yang, X., Luo, H., Li, Q., Zhu, W., Fu, L., Chen, L., Li, X., Su, H., Zhang, L., & Huang, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202502661r · Cited by 5
Mohanty, A., Bashir, B., Kolekar, K. A., Acharya, A., Gulati, M., Chaitanya, M., Gupta, M., Patle, D., Gupta, G., & Singh, S. K. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02015-2 · Cited by 4
“The inconsistent appearance of PCOS symptoms among patients hinders the application of general treatment protocols (Armanini et al. 2022).”
The Efficacy of Metformin and Exenatide in Polycystic Ovary Syndrome (PCOS) Patients
Kesavan, S., Chaudhry, G.-E.-S., Akim, A. M., & Ranneh, Y. (2023) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v64i2.27302 · Cited by 7
Alessandri, G., Mancabelli, L., Fontana, F., Lepore, E., Forte, G., Burratti, M., Ventura, M., & Turroni, F. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14540 · Cited by 7
Management of Hypertension in Patients With Polycystic Ovarian Syndrome: A Mini-Review
Liaghatdar, A., Mazaheri‐Tehrani, S., & Fakhrolmobasheri, M. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000635 · Cited by 4
Butler, A. E., Moin, A. S. M., Sathyapalan, T., & Atkin, S. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042409 · Cited by 5
“…features including T2D, hypertension, fatty liver disease and cardiovascular disease [1] in women with polycystic ovary disease (PCOS) that is thought to be related to the degree of insulin resistance and inflammation driven by obesity [1,2], characteristics typically found in the condition.”
BackgroundmiRNAs in ovarian disorders: Small but strong cast
Tafazoli, P., Rad, H. M., Mashayekhi, M., Siadat, S. F., & Fathi, R. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155709 · Cited by 4
Treatment of Qin Gui Wan (QGW) in PCOS abnormal oocytes development via AMPK/PGC-1ɑ pathway
Li, X., Cui, Y., Zhang, C., Zang, W., Cheng, Y., Yang, C., Zhang, S., Yu, X., & Gao, L. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119434 · Cited by 5
Chen, S., Han, L., Ying, Y., Xi, H., Zheng, J., Gong, C., Wang, S., Tang, Y., Zhao, J., Ge, R.-S., et al. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01774-4 · Cited by 4
“It has been reported that infertility in PCOS patients is frequently linked to a higher BMI and a long infertility duration [1] .”
Kuang, J., Luo, J., He, X., Yu, T., Zhou, Y., Zhang, X., Liu, Z., & Chen, T. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.107061 · Cited by 4
Exosomes for Polycystic Ovary Syndrome Treatment: Mechanisms and Therapeutic Potential
Liu, P., Sha, Y., Yang, H., & Liu, T. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s574044 · Cited by 5
“24 An imbalance in the hypothalamic–pituitary–ovarian axis plays a crucial role in endocrine dysfunction in PCOS.”
Popa, E., Chiş-Şerban, A.-A., & Coman, A. E. (2023) · Medic ro · doi:10.26416/med.151.1.2023.7837 · Cited by 3
da Silva, J. V. M. B., Veiga, A. C., Philbois, S. V., Ribeiro, V. B., Aguilar, B. A., Paixão, T. E. V., Chinellato, N. T., Delgado, J. C. S., Gastaldi, A. C., & de Souza, H. C. D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15163 · Cited by 6
“However, studies suggest that insulin resistance may be partially related to the aetiology of the problem [26].”
Pereira, J. D., Magalhães, F. M. V., Tameirão, F. M. S., Soriani, F. M., Jorge, K. T. D. O. S., dos Reis, F. M., Cândido, A. L., Comim, F. V., & Gomes, K. B. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112492 · Cited by 3
Morrone, P., Caroppo, F., Pedrini, A. D., Colletti, A., & Baj, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157538 · Cited by 3
“…(IR) is associated with decreased levels of sex hormone-binding globulin (SHBG), elevated concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and a subsequent increase in ovarian androgen synthesis, which may contribute to the development of hyperandrogenism [18,19].”
Ye, J., Guo, H., Zeng, Q., Gan, Z., Jin, Q., Su, H., & Lin, H. (2025) · Medicine · doi:10.1097/md.0000000000044441 · Cited by 3
Kaur, K. K. (2024) · Women s Health Science Journal · doi:10.23880/whsj-16000207 · Cited by 3
Validation of mitochondrial biomarkers and immune dynamics in polycystic ovary syndrome
Shen, H., Zhang, Y., Wang, X., Li, M., Liu, Z., Wang, Y., Ye, J., Wu, H., & Li, M. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13847 · Cited by 3
Morshedzadeh, N., Behrouz, V., & Ahmadi, A. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-24046-z · Cited by 3
“Furthermore, chronic low-grade inflammation is commonly observed in this population, contributing to metabolic dysregulation and an increased risk of comorbidities such as T2DM and cardiovascular disease 13 .”
Femi-Olabisi, F. J., Oyerinde, O. R., Faokunla, O. O., Omar, S. A., Igene, P. E., Asaluwala, O. E., Adeoye, B. O., & Oladoye, O. O. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100245 · Cited by 3
Motafeghi, F. S., Akbarzadeh, M., Talebi, S., Habibi, D., Fateh, S. T., Majd, H. A., Hedayati, M., Azizi, F., DANESHPOUR, M. S., & Tehrani, F. R. (2025) · Intern J Endocrinol Metab · doi:10.5812/ijem-159124 · Cited by 3
Chávez-Díaz, M. F., Ortiz-Rodríguez, B., Fierro, L. G. D. L., Luján, R. C., & Legleu, C. E. C. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251372517 · Cited by 3
Wang, Q., Liang, J., Liu, Q., Liu, H., Bai, H., Huang, W., & Fan, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1644373 · Cited by 2
Sigudu, T. T., Mkhatshwa, T. N., Monyeki, K. D., & Matshipi, M. (2025) · Critical Public Health · doi:10.1080/09581596.2025.2583607 · Cited by 2
“…on metabolic disorders in south africa, there remains a paucity of data evaluating lipid-based markers of iR in young, semi-rural populations (armanini et al., 2022; li et al., 2022). this study addresses this gap by evaluating tG, hDl-c, and the tG/hDl-c ratio as predictors of insulin…”
PCOS phenotypes and hematological immune-inflammatory indices: A comparative evaluation
Kından, A., Kından, G., Soysal, Ç., & Turan, V. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104823 · Cited by 6
Pulluparambil, S. J., & Bhat, S. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106933 · Cited by 2
Hou, Z., Hua, Y., Gao, S., Si, F., Wang, S., Jin, C., He, Z., Zhang, Z., & Chen, Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02017-w · Cited by 4
“Furthermore, existing theories often treat these factors as equal contributors without proposing a hierarchical regulatory structure or identifying a potential upstream initiator [18].”
Time Perspective as a Mediator of Depressive Symptoms in Patients with Polycystic Ovary Syndrome
Adamczak, A., Płotek, W., Głowińska, A., Sobol, M., Wysocka, E., Polak, G., Dymanowska-Dyjak, I., Spaczyńska, J., Adamczak, Ł., & Banaszewska, B. (2023) · Healthcare · doi:10.3390/healthcare11070993 · Cited by 5
“Beyond the multifactorial physiopathology of PCOS and depression, the diagnosis can also be complex [34,35].”
BackgroundStatins for women with polycystic ovary syndrome not actively trying to conceive
Xiong, T., Fraison, É., Kolibianaki, E., Costello, M., Venetis, C. A., & Kostova, E. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008565.pub3 · Cited by 4
Farhadi‐Azar, M., Noroozzadeh, M., Mousavi, M. A., Naz, M. S. G., & Tehrani, F. R. (2024) · Experimental Physiology · doi:10.1113/ep091912 · Cited by 3
“Studies have demonstrated that excessive androgen exposure in women with PCOS increases the risk of developing metabolic disorders such as IR, T2DM and dyslipidaemia (Armanini et al., 2022; Chen & Pang, 2021; Condorelli et al., 2018).”
Moradi, R., Kashanian, M., Yarigholi, F., Pazouki, A., & Sheikhtaheri, A. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11640-5 · Cited by 2
“In addition, remission of T2DM and/or insulin resistance may lead to potential fertility after MBS [35].”
Yu, S., & Yuan, Y. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07975-5 · Cited by 2
“…they were not identified as a risk factor in either analysis, possibly due to the interplay between insulin resistance and hyperandrogenism—since androgens can drive insulin resistance in PCOS [28], the influence of fasting insulin may be overshadowed by the more prominent role of testosterone.”
MODERN ASPECTS OF TREATMENT OF WOMEN WITH POLYCYSTIC OVARY SYNDROME
Semenyna, H. (2023) · GRUNDLAGEN DER MODERNEN WISSENSCHAFTLICHEN FORSCHUNG · doi:10.36074/logos-31.03.2023.50 · Cited by 2
Intervention is needed in polycystic ovary syndrome for prevention of cardiovascular diseases
Gersh, F. L., Lavie, C. J., & O’Keefe, J. H. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf007 · Cited by 5
Estimation the level of Neudesin in Polycystic ovarian syndrome patients
Salih, S. I., & Al-Dujaili, A. N. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202410804012 · Cited by 1
Mashhadi, F., Ghaebi, N. K., Roudi, F., & Nematy, M. (2024) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-024-01997-3 · Cited by 1
“Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of childbearing age, is now recognized as a complex condition with reproductive, endocrine, and metabolic manifestations [1–3].”
Liu, F., Tian, L., Zhang, Y., Deng, W., Xu, X., Zou, Y., & An, R. (2024) · Journal of Proteomics · doi:10.1016/j.jprot.2024.105332 · Cited by 2
Ling, S., Huang, L.-Y., Lia, T., Xie, D., Xiao, Q., Tian, C., & Li, Q. (2024) · Medicine · doi:10.1097/md.0000000000040162 · Cited by 2
“[6] Metabolic syndrome (MetS) is a complex disease in which protein, fat, carbohydrates, and other substances are metabolized in a disordered way.”
BackgroundNiinuma, S. A., Habib, H., Takemoto, A. S.-N., Das, P., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2025) · Cells · doi:10.3390/cells14050377 · Cited by 1
İbanoğlu, M. C., Yildiz, A. G., Tatar, O. B., Seçkin, B., Çiçek, T., & Üstün, Y. E. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2501694 · Cited by 1
“Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by menstrual irregularities, anovulation, hyper-androgenism (symptoms such as hirsutism or acne), micropolycystic ovaries and metabolic abnormalities [1].”
Luo, M., Tian, X., Li, L., Zhang, G., Liu, W., Mei, L., Li, H., You, X., Zhang, D., Zhou, M., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1633254 · Cited by 2
Natural Oil and Polycystic Ovary Syndrome: A Comprehensive Review of Therapeutic Benefits
Kumari, P., Barbhuiya, P. A., Warjri, I., & Pathak, M. P. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266370871250726131232 · Cited by 1
Krishana, S., Sarvadeo, S. S., Sharma, S., & Sharma, S. (2025) · Computational Intelligence · doi:10.1111/coin.70122 · Cited by 2
“Secondly, the emphasis on reproductive features may overlook the broader metabolic and cardiovascular aspects of PCOS, limiting the comprehensive understanding of the condition [20, 21].”
Khurshid, F., Arshad, I., Zafar, H. A., Qayyum, S., Hadi, A., Khurshid, A., & Tariq, S. (2025) · medtigo Journal of Medicine · doi:10.63096/medtigo3062338 · Cited by 1
Hamad, S. S., & Ahmed, S. (2025) · Middle East Fertility Society Journal · doi:10.1186/s43043-025-00243-8 · Cited by 1
“Nonetheless, some studies have been predicted that women with PCOS are overweight and have IR, while some persons of lean women may have normal insulin sensitivity [22, 23].”
Farooq, U., Hasan, N., Ali, A., Hasan, N., Mohapatra, S., Jain, P., Mirza, M. A., Ali, A., & Iqbal, Z. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2551321 · Cited by 1
“…disorders of PcOs. henceforth, the research focuses on the epicentre of disease i.e. insulin resistance and inherent myoinositol (Mi) deficiency [9]. the optimised pharmaceutical formulation was designed as a sustained-release product that can be self-administered easily with a reduced…”
Upadhyay, S., Mazumder, A., & Das, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128382284250822045319 · Cited by 1
Jiang, Q. Y., Pu, D., Hu, Y., Wu, R., Jiang, C., Yuan, S., Zhu, X., & Xu, L. (2025) · Medicine · doi:10.1097/md.0000000000046163 · Cited by 1
“[33] Elevated insulin levels promote the apoptosis of ovarian granulosa cells, which in turn inhibits ovulation.”
Metformin in the Treatment of Polycystic Ovary Syndrome: A Literature Review
Juda, A., Rojek, K., Kamińska, M., Strzoda, A. J., Strzoda, A., Sowiński, W. J., Zdybel, M., & Strzoda, A. (2025) · International Journal of Infertility & Fetal Medicine · doi:10.5005/jp-journals-10016-1397 · Cited by 1
Hosein, M.-R., & Housein, Z. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11436-3 · Cited by 1
Biomarkers for effective prognosis of polycystic ovary syndrome: a full review
Singh, I., Pant, A., & Maurya, P. K. (2026) · Biomarkers in Medicine · doi:10.1080/17520363.2026.2622044 · Cited by 2
Metadata
- Authors
- Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Armanini, Decio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 23
- Issue
- 8
- Pages
- 4110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9030414
- OpenAlex
- W4224247712
- Semantic Scholar
- 6ba01eafb58b7f3a48fb9c3789a3b5c603a63b92
- Cited by
- 324
- References
- 85
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 82 · 2023: 58 · 2022: 13
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, insulin resistance, inflammation, hyperandrogenism, PCOS pathogenesis, PCOS diagnosis, PCOS treatment, androgen receptor antagonists, metabolic disorders, oligoanovulation, PCOS phenotypes
- MeSH terms
- Female, Humans, Inflammation, Insulin Resistance, Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
